Treatment Trials

2 Clinical Trials for Various Conditions

Focus your search

      TERMINATED
      (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC
      Description

      This is a Phase 1/2, open-label, first-in-human (FIH) study is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of BLU-701 as monotherapy or in combination with either osimertinib or platinum-based chemotherapy in patients with EGFRm NSCLC.

      Conditions
      Lung NeoplasmCarcinoma, Non-Small-Cell LungRespiratory Tract NeoplasmsNeoplasmsNeoplasms by SiteLung DiseasesRespiratory Tract DiseasesCarcinoma, BronchogenicBronchial NeoplasmsAdenocarcinomaCarcinomaNeoplasms by Histologic TypeNeoplasms, Nerve TissueEGFR C797SEGFR C797AEGFR L858REGFR Exon 19 DeletionEGFR Gene MutationEGF-R Positive Non-Small Cell Lung CancerEGFR Mutation Resulting in Tyrosine Kinase Inhibitor ResistanceEGFR Activating MutationThoracic NeoplasmsAntineoplastic AgentsProtein Kinase InhibitorsEGFR C797GEGFR C797XNon Small Cell Lung Cancer
      Talk to us
      ACTIVE_NOT_RECRUITING
      Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)
      Description

      Phase 2 Platform Study in Patients with Advanced Non-Small Lung Cancer who progressed on First-Line Osimertinib Therapy. This study is modular in design, allowing evaluation of the efficacy, safety and tolerability of multiple study treatments.

      Conditions
      Non-Small Cell Lung Cancer
      Talk to us